Massive Bio

Executive Summary

Massive Bio is an AI-powered digital health platform that matches cancer patients to appropriate clinical trials by analyzing their medical records against a comprehensive database of active trials worldwide. Founded in 2015 and headquartered in New York, the company addresses a critical bottleneck in oncology: fewer than 5% of cancer patients enroll in clinical trials, often due to lack of awareness or geographic barriers. Massive Bio's machine learning algorithms enable rapid, personalized trial recommendations, reducing the time and cost for sponsors to recruit patients. The platform serves as a bridge between patients, physicians, and biopharma companies, aiming to democratize access to novel therapies. With a focus on scalability, Massive Bio has the potential to improve trial enrollment rates, accelerate drug development, and generate substantial value for stakeholders across the oncology ecosystem. Despite its compelling value proposition, Massive Bio operates in a competitive landscape with other trial-matching platforms, such as TrialScope and Deep 6 AI. The company has not disclosed funding or revenue figures, suggesting it remains in a growth or early commercial stage. To gain traction, Massive Bio must secure partnerships with large pharmaceutical companies, expand its trial database globally, and demonstrate measurable improvements in enrollment metrics. The company's next milestones likely include a significant funding round to fuel sales and technology development, as well as strategic alliances with major oncology research centers. If successful, Massive Bio could become a key infrastructure player in clinical research, addressing the underserved need for patient-centric trial access.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership for Clinical Trial Matching60% success
• H2 2026Series B Funding Round50% success
• 2027Expansion into EU or Asia-Pacific Markets40% success